{"pageContent": "Introduction: Prostate cancer is a common malignancy with highly variable clinical presentation and outcomes. Diagnosis and management remain a challenge and at times become highly controversial. Novel biomarker assays have shown promise as an adjunctive tool to aid in patient shared decision-making, risk stratification, and disease management. This presentation at the 2020 Jefferson Urology Symposium provided a review of current commonly used biomarkers for prostate cancer.", "metaData": {"source": "RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans\nhttps://pubmed.ncbi.nlm.nih.gov/18189233/"}}